SOT 201
Alternative Names: SO C108; SOT-201Latest Information Update: 09 May 2024
At a glance
- Originator SOTIO
- Class Antineoplastics; Cytokines; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT06163391)
- 13 Oct 2023 SOTIO plans a phase I clinical trial for SOT 201 in Cancer in the second quarter of 2024 (Parenteral)
- 08 Apr 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)